Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNB4 | O00305 | 4/20 | 0.46 |
| ▸ | CACNA1A | O00555 | 4/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.46 |
| ▸ | CACNG3 | O60359 | 4/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 4/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.46 |
| ▸ | CACNB3 | P54284 | 4/20 | 0.46 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.46 |
| ▸ | CACNG7 | P62955 | 4/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 4/20 | 0.46 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.46 |
| ▸ | CACNG1 | Q06432 | 4/20 | 0.46 |
| ▸ | CACNB2 | Q08289 | 4/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 4/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.46 |
| ▸ | CACNA1E | Q15878 | 4/20 | 0.46 |
| ▸ | CACNA2D4 | Q7Z3S7 | 4/20 | 0.46 |
| ▸ | CACNA2D3 | Q8IZS8 | 4/20 | 0.46 |
| ▸ | CACNG8 | Q8WXS5 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178385 | 0.93 | F2R (0.50) | ALDH1A1KDM4ECYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4316805 | 0.92 | GAA (0.46) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL4174366 | 0.80 | NPY5R (0.46) | ALDH1A1KDM4EPOLBGAACYP1A2 | |
| SCHEMBL3386168 | 0.76 | POLB (0.48) | ALDH1A1KDM4ECYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4182812 | 0.74 | POLB (0.48) | ALDH1A1KDM4ECYP2C9CYP2C19CYP3A4 | |
| SCHEMBL14583991 | 0.73 | SLC22A12 (0.56) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL3383808 | 0.71 | GAA (0.50) | ALDH1A1KDM4EPOLBGAACYP1A2 | |
| SCHEMBL12340155 | 0.71 | F2R (0.67) | F2RF2 | |
| SCHEMBL2776874 | 0.71 | ABL1 (0.53) | ALDH1A1 | |
| SCHEMBL16629103 | 0.71 | POLB (0.55) | ALDH1A1CYP2C19POLBCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268789-B2 | PAR-2 antagonists | KOWA COMPANY, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268789-B2 | PAR-2 antagonists | KOWA COMPANY, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| EP-1806141-B1 | PAR-2 ANTAGONISTS | KOWA CO (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1806355-A1 | PROCESS FOR PRODUCTION OF (1,3-DISUBSTITUTED INDOLYL)- UREA DERIVATIVES, INTERMEDIATES THEREFOR, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATES | Kowa Company Ltd. (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1806141-A1 | PAR-2 ANTAGONISTS | Kowa Company, Ltd. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | WEE1, WASF2, IDO1 | CACNB4 3899/4885CACNA1A 4822/4885CACNA1G 4517/4885 |
| US-20090012006-A1 | Par-2 Antagonists | F2RL1, F2R, F2RL3 | CACNB4 4487/4885CACNA1A 3862/4885CACNA1G 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.